ensitrelvir
Jump to navigation
Jump to search
Indications
- investigational treatment of outpatient Covid-19
- may reduce long Covid-19 symptoms
- non-inferior to Paxlovid (nirmatrelvir/ritonavir) for improving SARS CoV-2 viral clearance at 5 days[3]
* reduces symptoms of mild-moderate Covid-19 by ~1 day
* reduces number of days patients test positive for Covid-19
Dosage
* median time to resolution of Covid-10 symptoms 24 hours sooner than placebo
* SARS-CoV2 viral titers negative within a median of 36 hours vs 65 hours with placebo
* 87% reduction of infectious SARS-Cov2 at day 4
Adverse effects
- was well tolerated, no serious treatment-related adverse events or deaths
- most common treatment-related adverse events
- temporary decreases in HDL cholesterol increased serum triglycerides
Mechanism of action
- 3C-like protease inhibitor that targets SARS-Cov2
- maintains activity across different variants including Omicron
More general terms
References
- ↑ Hein I Investigational Oral Antiviral Shows Promise in COVID Outpatients. Exploratory analyses also point to possible reduction in long COVID symptoms. MedPage Today February 22, 2023 https://www.medpagetoday.com/meetingcoverage/croi/103222
- ↑ Lenharo M COVID pill is first to cut short positive-test time after infection Nature News 2023. March 3. https://www.nature.com/articles/d41586-023-00548-6
- ↑ 3.0 3.1 Schilling WHK, Jittamala P, Wongnak P, et al. Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00482-7. PMID: https://pubmed.ncbi.nlm.nih.gov/41082886 Free article https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00482-7/fulltext